Finally, we demonstrated the in vivo significance of this procedure by showing that SHC-MSCs and PLK1-overexpressing MSCs exhibited an enhanced therapeutic potency in a humanized mouse model of GVHD. This evidence concerns the gene PLK1 and graft versus host disease.